Literature DB >> 15095297

Reversible lymphomagenesis in conditionally c-MYC expressing mice.

Dragan Marinkovic1, Tatjana Marinkovic, Bettina Mahr, Jochen Hess, Thomas Wirth.   

Abstract

It is well documented that deregulation of MYC leads to tumor development, yet many aspects of this process are only partially understood. We have established a transgenic mouse model in which c-MYC is conditionally expressed in lymphoid cells using the tetracycline-regulated system of gene regulation. Mice with continuously expressed transgenic c-MYC died of invasive T- or B-cell lymphomas within 4 months. Lymphomas developing in transgenic mice were c-MYC dependent since doxycycline treatment led to tumor regression. Using transplantation of established tumor cell lines labeled with GFP, we followed the fate of neoplastic cells in recipients upon MYC inactivation. This approach allowed us to elucidate both apoptosis and differentiation as mechanisms of tumor elimination. Comparative genomic hybridization (CGH) and FISH analyses were performed in order to analyze possible chromosomal aberrations induced by c-MYC. We observed that overexpression of c-MYC is sufficient to induce recurrent patterns of genomic instability. The main observation was a gain of genomic material that corresponded to chromosome 15 in several T-cell tumors, which could be identified as trisomy. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095297     DOI: 10.1002/ijc.20099

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus.

Authors:  Sherif F Louis; Bart J Vermolen; Yuval Garini; Ian T Young; Amanda Guffei; Zelda Lichtensztejn; Fabien Kuttler; Tony C Y Chuang; Sharareh Moshir; Virginie Mougey; Alice Y C Chuang; Paul Donald Kerr; Thierry Fest; Petra Boukamp; Sabine Mai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

2.  Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.

Authors:  Steven I Park; Carolina P Lin; Natalie Ren; Steven P Angus; Dirk P Dittmer; Michael Foote; Trevor Parton; Aadra P Bhatt; Yuri D Fedoriw; Daniel P Roth; Marissa L Cann; Gary L Johnson; Blossom Damania
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

3.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 4.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 5.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

6.  Differential cellular responses by oncogenic levels of c-Myc expression in long-term confluent retinal pigment epithelial cells.

Authors:  Yiping Wang; Xiangdong Cheng; Muhammad Kaleem Samma; Sam K P Kung; Clement M Lee; Sung Kay Chiu
Journal:  Mol Cell Biochem       Date:  2017-11-29       Impact factor: 3.396

7.  Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.

Authors:  Duonan Yu; Michael Dews; Andrea Park; John W Tobias; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

8.  DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.

Authors:  Jinfei Xu; Joseph R Testa
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

Review 9.  SGF29 and Sry pathway in hepatocarcinogenesis.

Authors:  Nobuya Kurabe; Shigekazu Murakami; Fumio Tashiro
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Identification of novel Myc target genes with a potential role in lymphomagenesis.

Authors:  Dragan Marinkovic; Tatjana Marinkovic; Eniko Kokai; Thomas Barth; Peter Möller; Thomas Wirth
Journal:  Nucleic Acids Res       Date:  2004-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.